ImmunityBio Faces Class Action After FDA Flags Misleading Cancer Claims, Shares Plummet

ImmunityBio's Legal Troubles and What It Means for Investors

ImmunityBio, Inc., trading under the NASDAQ symbol IBRX, has found itself embroiled in a securities class action lawsuit that has shaken investor confidence and led to a dramatic drop in its stock price. The lawsuit, filed by the national law firm Hagens Berman, seeks to represent all investors who purchased or acquired ImmunityBio securities during the class period, which extends from January 19, 2026, to March 24, 2026. The company is primarily known for its work in the field of biotechnology, developing innovative immunotherapies aimed at activating the immune system for cancer treatment.

The catalyst for the class action stems from an FDA warning regarding claims made by Dr. Patrick Soon-Shiong, ImmunityBio’s executive chairman and Chief Scientific and Medical Officer. Reports surfaced following a podcast episode and TV advertisement where Dr. Soon-Shiong asserted that their flagship product, Anktiva, approved for treating non-muscle invasive bladder cancer (NMIBC), could potentially treat a wide array of cancers. The FDA took severe objection to these statements, labeling them misleading, thus prompting an official warning letter. This letter declared that the representations made through these media platforms falsely implied that Anktiva could cure all forms of cancer, which the FDA noted had not been substantiated by any clinical data.

On March 24, 2026, amidst the backlash from the FDA, ImmunityBio’s stock plunged over 21%, erasing nearly $2 billion from its market capitalization. Such a significant financial loss has rallied investors to seek justice through the legal system, claiming that they were misled about the efficacy of Anktiva and its various indications in treating cancer.

The legal team at Hagens Berman has urged affected investors to come forward, asserting that the firm is keen to investigate and build a case against ImmunityBio for potential violations of federal securities laws. This investigation may also extend to gather insights from witnesses who could offer crucial information, further emphasizing the seriousness of the situation.

In the wake of these developments, ImmunityBio remains under scrutiny not just from disgruntled investors but also from regulatory bodies concerned with public health. With allegations stating that the company’s promotional materials were misleading and omitted key information regarding Anktiva's FDA-approved indications, the implications could extend far beyond financial losses. Observers in the medical and scientific communities are also observing this scenario closely, given the ethical considerations surrounding drug promotion and patient safety.

The fallout from ImmunityBio’s troubles extends to the larger biotech industry, which consistently faces the challenge of balancing innovation with truthful representation. As investors grapple with the uncertainty, many are left pondering how potentially misleading claims can impact public trust in life-saving treatments. The next steps for ImmunityBio are critical; they will not just determine the future of the company but could also reshape how biotechnology firms communicate their findings and product claims.

As Hagens Berman continues its investigation, investors are encouraged to stay informed about their rights and options. Whistleblower protections and incentives may also apply in this case, allowing those with non-public information regarding ImmunityBio to potentially receive financial rewards for their assistance in the investigation.

In essence, the ImmunityBio scenario is a cautionary tale within the biotech sector, serving as a reminder that transparency and accountability are imperative in the fight against diseases. Investors and stakeholders alike await further developments, not only regarding the class action but also concerning the overall integrity of pharmaceutical and biotechnological advancements.

For investors who are affected, it’s crucial to remain vigilant and knowledgeable about the evolving landscape surrounding ImmunityBio’s case. Advocates for corporate accountability such as Hagens Berman continue to stand at the forefront of this issue, emphasizing the importance of protecting investors from potential misrepresentation within the market.